Tefibazumab, formerly known as INH-H2002, represents a novel therapeutic approach targeting complement factor H, specifically its ability to attach with C5. This immunoglobulin is engineered to inhibit the production of the C5b-9 membrane attack complex, a significant driver of cellular injury in various conditions . Early research suggest a possib